TABLE 1

MIC distributions for NBTI 5463 against key Gram-negative bacterial pathogens

Bacterial species (no. of strains)aAgentMICb (μg/ml)
MIC50MIC90Range
Escherichia coli (20)NBTI 5463120.5–4
Levofloxacin≤0.0616≤0.06–32
Cefepime≤0.06>64≤0.06–>64
Gentamicin120.05–>64
Klebsiella pneumoniae (20)NBTI 54634160.5–>64
Levofloxacin0.564≤0.06–>64
Cefepime0.25>64<0.06–>64
Gentamicin0.5640.25–>64
Proteus spp. (30)NBTI 5463280.125–>64
Levofloxacin0.0620.015–4
Ceftazidime0.060.250.03–32
Amikacin481–16
Enterobacter spp. (30)NBTI 54634160.5–32
Levofloxacin0.12540.03–4
Ceftazidime8320.25–32
Amikacin282–64
Citrobacter spp. (30)NBTI 54630.540.06–8
Levofloxacin0.0340.008–4
Ceftazidime0.5320.125–32
Amikacin280.5–>64
Pseudomonas aeruginosa (21)NBTI 54630.520.125–4
Levofloxacin1320.125–32
Cefepime8161–64
Gentamicin4>641–>64
Stenotrophomonas maltophilia (20)NBTI 5463480.25–32
Levofloxacin0.520.125–8
Cefepime64>6432–>64
Gentamicin64>644–>64
Acinetobacter baumannii (20)NBTI 54638640.125–>64
Levofloxacin832<0.06–>64
Cefepime16>64<0.06–>64
Gentamicin64>641–>64
  • a Bacterial strains from the AstraZeneca internal collection of clinical isolates.

  • b MICs determined in Mueller-Hinton broth according to CLSI methods.